NANOVIRICIDES, INC.
No enriched coverage for $NNVC in the last 7 days.
No SEC Form 4 filings for $NNVC in the last 30 days.
See all $NNVC insider activity →NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering New York, July 24, 2026 — NanoViricides, Inc. (NYSE American: NNVC) (“NanoViricides” or the “Company”), a clinical stage, leading global pioneer in the development of broad-spectrum antiviral
NanoViricides (NYSE American: NNVC) priced a registered direct offering with a single institutional investor for gross proceeds of about $3.8 million. The company will sell 2,516,339 shares, or pre-funded warrants, plus warrants for the same number of shares at a $1.75 exercise price, expiring about 5.5 years. Closing is expected around July 27, 2026.
NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2620770d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 NANOVIRICIDES, INC. Common Stock (par value $0.00001 per share) At Market Issuance Sales Agreement July 17, 2026 D. Boral Capital LLC 590 Madison Avenue, 39 th Floor New York, New York 10022 Ladies and Gentlemen: NanoViricide
Recent NNVC coverage spans corporate actions, financial news and market movers.
The filing indicates a new equity-linked financing transaction (warrants and pre-funded warrants), which can be dilutive and may pressure near-term valuation.
The dilutive equity raise and warrant terms are likely to pressure near-term valuation, while providing cash runway.
The filing discloses a new equity issuance mechanism (ATM), which can increase dilution risk and affect near-term price dynamics.
Initiating coverage with a defined target can drive near-term sentiment and trading activity, but it is not a fundamental catalyst like trial data or financing.
Ebola read-across plus logistical readiness can increase perceived probability of near-term clinical engagement.
AlphAI scores every news story that mentions NNVC with an AI model for sentiment and relevance, and aggregates insider trades from NANOVIRICIDES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering New York, July 24, 2026 — NanoViricides, Inc. (NYSE American: NNVC) (“NanoViricides” or the “Company”), a clinical stage, leading global pioneer in the development of broad-spectrum antiviral
3 min readNanoViricides (NYSE American: NNVC) priced a registered direct offering with a single institutional investor for gross proceeds of about $3.8 million. The company will sell 2,516,339 shares, or pre-funded warrants, plus warrants for the same number of shares at a $1.75 exercise price, expiring about 5.5 years. Closing is expected around July 27, 2026.
4 min readNANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2620770d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 NANOVIRICIDES, INC. Common Stock (par value $0.00001 per share) At Market Issuance Sales Agreement July 17, 2026 D. Boral Capital LLC 590 Madison Avenue, 39 th Floor New York, New York 10022 Ladies and Gentlemen: NanoViricide
2 min readNanoViricides, Inc. (NNVC) said an independent analyst at Noble Capital Markets initiated coverage with an “Outperform” rating and a $6.00 target price, based on its estimates. The company also published a “Fireside Chat” interview with President Anil Diwan discussing NV-387, other programs, and FDA orphan drug and rare pediatric disease designation topics.
3 min readBiotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).
6 min readNanoViricides highlights the urgent need for broad-spectrum antivirals, especially during the current severe influenza season dominated by the H3N2 variant, against which seasonal vaccines are less effective. The company's drug candidate, NV-387, is presented as a promising solution due to its broad-spectrum efficacy against influenza, RSV, and Coronaviruses, operating through a mechanism that viruses are unlikely to escape. NV-387 is currently in Phase II clinical trials and is being positioned as a potential first-line empiric therapy for respiratory viral infections.
3 min readNanoViricides announced that its clinical lead drug NV-387 demonstrated strong antiviral activity against the Measles virus in cell culture and a humanized animal model, significantly protecting lungs from damage. NV-387 achieved this by directly reducing the virus and preventing systemic cellular damage, acting via a unique "Re-Infection Inhibition" mechanism. The drug completed a Phase I clinical trial safely and is being developed as a broad-spectrum antiviral for various respiratory infections, including Measles.
2 min read